Definitive Healthcare Corp. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 28/100
What the filing says
Definitive Healthcare reported Q2 2026 revenue of $55.2M (down from $60.8M in Q2 2025, a 9% decline). Adjusted EBITDA was $14.6M at 26% margin, compared to $18.7M at 31% margin in Q2 2025. Net loss improved to $(7.5)M from $(9.3)M. The company reaffirmed full-year 2026 guidance: revenue $220–$222M, adjusted EBITDA $57–$59M at 26–27% margin, and adjusted net income $27–$29M ($0.18–$0.20 per diluted share on ~145.1M shares). Key wins included a six-figure three-year win-back deal and a multi-hundred-thousand-dollar expansion from a population-intelligence customer.
Why this rating
9% YoY revenue decline and margin compression (31%→26%) are concerning. However, guidance intact and profitability positive. For $154M market-cap company, $5.6M quarterly revenue miss is material but not crisis; adjusted EBITDA margin still healthy. No major M&A, debt crisis, or leadership changes.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.